South Korea · Delayed Price · Currency is KRW D&D Pharmatech Company Description
D&D Pharmatech Inc. engages in the research and development and manufacturing of pharmaceuticals in South Korea.
It develops oral peptides, such as MET-002o, MET-224o, MET-097o, DD03, DD07, and DD14 programs for obesity indications in the development phase; injectable peptides, including DD01 for MASH indications; NLY12 and DD15 for obesity indications; and Pegsebrenatide (NLY01) for Parkinson’s and Alzheimer’s diseases.
The company is also involved in the development of TLY012, an injectable protein for systemic sclerosis, liver fibrosis, and chronic pancreatitis indications; NLY02, an oral small molecule for PD and AD indications; and P4M01 for anti-microbial peptide indications.
In addition, it develops PMI07, PMI05, and PMI06 for solid tumor imaging biomarker indications; and PMI04 for neuroinflammation indications.
The company was founded in 2014 and is based in Seongnam-si, South Korea.
| Country | South Korea |
| Founded | 2014 |
| Industry | Biotechnology |
| Sector | Healthcare |
| CEO | Seul-ki Lee |
Contact Details
Address: 27, Geumto-ro 80beon-gil, Seongnam-si, 13453 South Korea | |
| Phone | 82 31 8019 7771 |
| Website | ddpharmatech.com |
Stock Details
| Ticker Symbol | 347850 |
| Exchange | KOSDAQ |
| Fiscal Year | January - December |
| Reporting Currency | KRW |
| ISIN Number | KR7347850000 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Seul-ki Lee | Chief Executive Officer |